Indications:
For reducing signs and symptoms and inhibiting the progress of
structural damage in patients with moderately to severely active
rheumatoid arthritis. In combination with methotrexate in patients
who do not respond to methotrexate alone. To reduce symptoms and
signs of moderately to severely active poly-articular-course
juvenile rheumatoid arthritis (JRA) in patients who have had an
inadequate response to one or more DMARDs.
Description:
Etanercept inhibits TNF activity by competitively binding to it
and preventing interactions with its cell surface receptors.
Elevated levels of TNF have been found in psoriatic skin lesions,
and in synovial explants and fluid from patients with psoriatic
arthritis.[5-7] Furthermore, TNF levels in the serum of patients
with plaque psoriasis, and in blister fluids of involved psoriatic
skin[9] have also been shown to be higher than in those of
controls. These values were significantly correlated with the
psoriasis area and severity index (PASI) scores, and TNF levels
were reduced in association with clinical resolution after
effective treatment.
The production of chemokines, and the expression of adhesion
molecules by keratinocytes and vascular endothelial cells can be
stimulated by TNF produced within psoriatic lesions. These signals
then cause recruitment of additional inflammatory cells into the
plaque. Krueger suggests that TNF may function as part of a
positive feedback loop, which acts to amplify and sustain the
inflammatory process within psoriatic plaques.[10] Biologic
responses that are induced or regulated by TNF are modulated by
etanercept. It may, therefore, serve to reduce inflammation within
plaques by breaking this cycle.
Dosage:
Adults: 25mg given twice weekly as a subcutaneous injection 72-96
hours apart. Methotrexate, glucocorticoids, NSAIDs, or analgesics
may be continued during treatment with etanercept. JRA patients:
For paediatric patients (4 to 17 years), dose is 0.4mg/kg (up to a
maximum of 25mg per dose) given twice weekly as a subcutaneous
injection 72-96 hours apart. Glucocorticoids, NSAIDs, or
analgesics may be continued during treatment with etanercept.
Presentations: Vial 1 ml
Note :This product
information is intended only for residents of the India.
Taj Pharmaceuticals Limited, medicines help to treat and prevent
a range of conditions—from the most common to the most
challenging—for people around the world.
Information for Health Care Professionals
*** Please consult local Prescribing
Information for any product before use. This website is an
international information resource for healthcare professionals
with an interest in disease management. This website is not
intended to replace the advice of a qualified healthcare
professional. Above brand is a trademark of the Taj group of
companies (Taj Pharmaceuticals Limited)
Quality
